204521-63-1

Basic information

• Product Name: Nε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-tert-butyl Ester
• Synonyms: 1-tert-butyl 2,5-dioxopyrrolidin-1-yl (2S)-2-hexadecanaMidopentanedioate;Nε-Hexadecanoyl-L-glutaMic Acid α-t-Butyl-γ-2,5-dioxopyrrolidin-1-yl-diester;Pal-Glu(OSu)-OtBu;Nε-Palmitoyl-L-glutamic Acid;N-Palmitoyl-L-glutamic acid alpha-tert- butyl ester gamma-succinimidyl ester;N-Palmitoyl-L-glutamic acid α-tert- butyl ester γ-succinimidyl ester≥ 99% (HPLC);Palmitoyl-Glu(OSu)-OtBu;Palm-L-Glu(OSu)-OtBu
• CAS NO: 204521-63-1
• Molecular Formula: C₂₉H₅₀N₂O₇
• Molecular Weight: 538.7165
• Product Categories: Amino Acids & Derivatives;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 204521-63-1.mol
• Article Data: 8

Chemical Properties

• Melting Point: 86.0 to 90.0 °C
• Appearance: /
• Density: 1.08±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, Refrigerator, Under Inert Atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly, Heated)
• PKA: 14.40±0.46(Predicted)
• CAS DataBase Reference: Nε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-tert-butyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: Nε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-tert-butyl Ester(204521-63-1)
• EPA Substance Registry System: Nε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-tert-butyl Ester(204521-63-1)

Safety Data

• Hazardous Substances Data: 204521-63-1(Hazardous Substances Data)

Usage

Description

Nε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-tert-butyl Ester is a white crystalline powder that serves as a key component in the development of lipophilic human glucagon-like peptide-1 (GLP-1) derivatives. Nε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-tert-butyl Ester is instrumental in enhancing the action profiles of these derivatives, leading to protracted effects that are beneficial in various applications.
Used in Pharmaceutical Industry:
Nε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-tert-butyl Ester is used as a pharmaceutical agent for the preparation of lipophilic human GLP-1 derivatives with protracted action profiles. Its incorporation into these derivatives allows for an extended duration of activity, which is advantageous in managing conditions such as diabetes and obesity.
Used in Antiobesity Applications:
In the realm of antiobesity treatments, Nε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-tert-butyl Ester is utilized as an active ingredient in the development of protracted-action GLP-1 derivatives. These derivatives have the potential to offer long-lasting weight management solutions, making them a promising avenue for addressing obesity and its associated health risks.
Chemical Properties:
As a white crystalline powder, Nε-PalMitoyl-L-glutaMic Acid γ-SucciniMidyl-α-tert-butyl Ester exhibits the necessary stability and purity required for pharmaceutical applications. Its solid-state form facilitates its incorporation into various formulations, ensuring consistent and reliable results in the development of lipophilic GLP-1 derivatives.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 536721-25-2 L-glutamic acid, N-(1-oxohexadecyl)-, 1-(1,1-dimethylethyl) ester 
• 57-10-3 1-hexadecylcarboxylic acid 
• 105832-38-0 O-(N-succinimidyl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 
• 45120-30-7 L-glutamic acid α-tert-butyl ester 
• 14464-31-4 palmitic acid N-succinimide ester 

Relevant articles and documents

AN IMPROVED PROCESS FOR PREPARATION OF LIRAGLUTIDE

The present invention relates to an improved process for the preparation of Liraglutide. The present invention further related an improved process for the preparation of substantially pure material having a purity of greater than or equal to 99.5% by HPLC.

Novel GLP-1 Analogues

The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.

INSULIN DIMER-INCRETIN CONJUGATES

Insulin dimers conjugated to peptides having at least one incretin activity are disclosed.